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Neglected and
Underappreciated—The Case of
Schistosomiasis
Recent systematic reviews [1,2] indicate
that the geographic extent and burden of
schistosomiasis exceeds official estimates.
The risk for infection is particularly
pronounced in sub-Saharan Africa, but
also exists in many parts of South
America, the Middle East, and Southeast
Asia. Collectively, close to 800 million
individuals are at risk of schistosomiasis,
and over 200 million people are infected
[2]. The disease can be controlled with
vigorous political and financial commit-
ment, but local elimination has proved
difficult in reality. The cost of treatment
with the only available drug—praziquan-
tel—has become affordable, and hence
preventive chemotherapy is being advo-
cated on a large scale [3]. However, a
strongly biased approach, devoid of any
emphasis on prevention, access to clean
water and improved sanitation, and snail
control, demands indefinite drug distribu-
tion [4,5]. Although praziquantel-based
morbidity control has proved successful, it
has an intrinsic weakness, which is inti-
mately related to its inadequate impact on
transmission even when chemotherapy is
provided according to schedules carefully
adjusted to the local setting [6].
Genuine change of the disease spectrum
in endemic settings demands lasting results
which can only be obtained by long-term
protection involving vaccination. An en-
tirely vaccine-based approach to schisto-
somiasis control is unrealistic, but we
advocate that acceptable protection could
be achieved by chemotherapy followed by
vaccination aimed at reducing, or mark-
edly delaying, the development of pathol-
ogy [7]. Thus, the issue is not vaccines
versus chemotherapy, but how to graft a
vaccine approach onto current schistoso-
miasis control programs. This, we believe,
would fit well with the scope of the
‘‘Schistosomiasis Research Agenda’’, par-
ticularly in the areas of ‘‘Basic Science’’,
‘‘Tools and Interventions’’, and ‘‘Disease
Burden’’ advanced by Colley and Secor in
their recent Policy Platform article in PLoS
Neglected Tropical Diseases [8] and the linked
Expert Commentary [9].
The True Impact of
Schistosomiasis
Currently, vaccines do not figure prom-
inently in the context of schistosomiasis
control. In fact, neither vaccines nor new
drug development are pursued with high
priority by funding bodies, industry, or
academia. There are two important rea-
sons for this. First, praziquantel is safe,
efficacious, and inexpensive (recently even
donated free of charge in some control
programs) and, as yet, there are no clear
indications of drug resistance. Second, a
low rank is awarded to schistosomiasis by
the disability-adjusted life year (DALY)
metric, an approach guiding the policies of
most organizations active in the public
health area, including the World Health
Organization (WHO) [10,11].
Figure 1 illustrates the impact according
to the DALY metric of the ten diseases
supported by the UNICEF/UNDP/World
Bank/WHO Special Programme for Re-
search and Training in Tropical Diseases
(TDR) in relation to research spending for
the biennium 2001–2002 [7] and 2007–
2008 [12]. The difference between the two
graphs in Figure 1 seems to indicate a move
away from a rigorous adherence to the
DALY metricasthekeytofunding thatwas
evident at the beginning of the new
millennium. Indeed, there are several
‘‘outliers’’ in the latest TDR budget, which
could be due to a desire to make a
difference where needed (e.g., onchocerci-
asis), while control successes in other areas
may have given the impression that re-
search is less needed there (e.g., schistoso-
miasis and lymphatic filariasis). In our
opinion, and that of others [1], the low
ranking of schistosomiasis does not appear
to be justified. First, research aimed at the
long-term control of schistosomiasis re-
mains important despite current successes.
Second, if all health problems due to this
disease were considered, it should actually
be inthe topcategorytogetherwithmalaria
and tuberculosis [1,13]. Currently, the
DALY measure for schistosomiasis only
includes overt signs of morbidity, while
more common sequelae such as anemia,
growth retardation, impaired cognitive
development, and exercise intolerance are
not [1,14]. In addition, future re-calcula-
tions of the global burden of schistosomiasis
and other neglected tropical diseases
(NTDs) should also consider the likely
influence of co-infection and co-morbidity
[14,15], and their relation to health pro-
motion strategies in endemic areas. Most
important from the control point of view,
however, is the observation that the
recurrent aggressive inflammation follow-
ing interrupted chemotherapy in 80% of
children living in high-transmission areas
[16] requires frequent praziquantel treat-
ment to avoid making the situation worse
than it might have been without any
intervention at all. This inflammatory
response, due to interference with the
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takes place during the course of natural
infection, severely exacerbates pathology in
epidemiological settings where treatment
schedules cannot be sustained.
Contemporary Control
Emphasis
Current funding for schistosomiasis is far
from negligible, but most of the money is
allocated for a single approach: the procure-
ment, distribution, and deployment of
praziquantel. Over the past five years, the
Schistosomiasis Control Initiative (SCI;
http://www.schisto.org/), which is funded
by the Bill& Melinda Gates Foundation, has
spent close to US$50 million for mass drug
administration targeting schistosomiasis and
soil-transmitted helminthiases in six African
countries. Although SCI is the architect of
one of the great control successes of modern
times, and has been awarded the Queen’s
2007 Anniversary Prize, the solution is
incomplete because transmission is only
marginally affected and the long-term
outlook limited by re-infection [6,15].
SCI will be continued, and its scope
expanded and increasingly integrated with
control efforts targeting other NTDs,
supported by additional funding from
multiple sources. Collaborative work in
this field includes a US$8.9 million grant
from Geneva Global awarded to the
Global Network for Neglected Tropical
Disease Control (GNNTDC; http://
gnntdc.sabin.org/) and a US$100 million
grant from the United States Agency for
International Development (USAID)
awarded to RTI International (http://
www.rti.org/) with the goal of treating 40
million individuals over a 5-year period
[17]. Most significantly, a US$350 million
new global initiative to combat NTDs was
announced by US President George W.
Bush earlier this year [18].
Is Schistosomiasis Vaccine
Development Justified?
It could be argued that the success of SCI
constitutes the justification needed for vac-
cine development, since an effective vaccine
would add the necessary long-term perspec-
tive presently lacking in schistosomiasis
control strategies. Moreover, the reposition-
ing of vaccines as the solution to a
Figure 1. Yardstick for Financial Resource Allocation Based on the Global Burden Awarded to Each Disease in TDR’s Portfolio in the
2001–2002 Biennium (Top) and the 2007–2008 Biennium (Bottom). The figures show that the diseases fall into two relatively distinct groups,
(i) well-funded (i.e., malaria and tuberculosis), and (ii) less well-funded, including leprosy, which is now targeted for elimination as a threat in public
health. Note the particularly low amounts currently allocated to schistosomiasis and lymphatic filariasis in relation to the estimated global burden of
these diseases.
doi:10.1371/journal.pntd.0000244.g001
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revitalizing concept in a field where control
activities have remained exclusively focused
on morbidity reduction for too long. The
revised strategy would combine immediate
opportunity with the need for longer term
support of ongoing discovery and skills
development.
Resistance against praziquantel in the
future cannot be ruled out even if, after
more than 20 years of large-scale applica-
tion in some places, there is still no clear-
cut evidence pointing in that direction.
However, if (when) resistance does occur,
a replacement drug must be available for
immediate implementation. Otherwise,
not only would the current strategy
collapse, but the integrated drug–vaccine
approach that we are advocating here
would also be seriously impaired. It is
therefore worrisome, from both of these
points of view, that praziquantel is the only
drug available at this juncture.
In contrast to the time before the advent
of recombinant techniques, we now have the
tools to produce particular biological mate-
rialsinlargeamountsat areasonablecost. In
addition, the complementary approach,
bypassing antigen preparation and relying
on injection of DNA itself, has gained wide
acceptance. Thanks to this technical pro-
gress, industrial vaccine production must
now be deemed realistic, while the argu-
ments supporting the possibility of succeed-
ing withinthe field of schistosomiasis remain
strong for the following reasons:
N humans living in endemic areas devel-
op some degree of protection naturally
with some becoming immune [19,20];
N irradiated cercariae confer .80%
protection in experimental animal
models [21];
N schistosomiasis vaccine candidates al-
ready exist, which produce $40%
protection in animal models [22]; and
N highly efficacious recombinant veteri-
nary vaccines against taeniid cestodes
have been developed [23].
The linking of vaccination with chemo-
therapy would reduce overall morbidity
and limit the impact of re-infection.
Therefore, although induction of consis-
tent, high-level protection has not been
recorded for any of the available candidate
vaccine antigens, the commonly reported
protection levels of ,40%–50% in exper-
imental animals [24] should, in our
opinion, be sufficient for a combined
drug–vaccine approach to improve signif-
icantly on the current strategy, which is
based on chemotherapy alone.
Vaccine development so far has been
focused on Schistosoma mansoni, resulting in
progress towards Phase I safety trials of
one vaccine candidate, the 14-kDa fatty
acid-binding protein (Sm14) [25]. The
other vaccine candidate to have entered
clinical trials, a 28-kDa glutathione-S-
transferase (Sh28GST, also known as
BILHVAX), is derived from S. haematobium
[26], a schistosome species otherwise
neglected with regard to vaccine develop-
ment, but which clearly is important for
future study, particularly as most human
cases of schistosomiasis are due to
S. haematobium [27]. For S. japonicum,a
number of promising vaccine candidates
already exist [22]. The fact that S. japonicum
infects a wide spectrum of final hosts is an
added challenge for control programs
[28], but is positive from the point of view
of vaccine development, since it permits a
step-wise tactic that would start with a
‘‘transmission-blocking’’ veterinary prod-
uct [29] before moving on to the human
vaccine. The possibility that this strategy
could pay off already before a human
vaccine is realized is supported by Chinese
studies showing that the animal–snail–
human transmission cycle is more prom-
inent than the human–snail–human one in
sustaining the infection [30,31].
New Approaches in Antigen
Discovery
The current Schistosoma vaccine candi-
dates may prove not to be the most
effective, and it is, therefore, important
to continue to identify new target antigens.
The generation of a large schistosome
transcriptome database and postgenomic
technologies, including DNA microarray
profiling, proteomics, glycomics, and im-
munomics, offer the necessary ancillary
information [22,32–34]. These new ap-
proaches in antigen discovery have the
potential to identify a new generation of
vaccine target molecules that may induce
greater potency than the current candidate
schistosome antigens [22]. Molecules con-
taining signal peptides and signal anchors
as predictors of excretory-secretory prod-
ucts, including enzymes and components
exposed on the schistosome tegument
(including receptors) that interact directly
with the host immune system, are highly
relevant targets for study [22,34].
Human Immune Responses to
Vaccine Candidate Antigens
The analysis of human antibody and
cytokine responses to candidate vaccine
antigens is a creditable way for establishing
bona fide vaccine candidates. Such a study,
focusing on the ten most promising schis-
tosome vaccine antigens, was carried out
over several years by the Egyptian Refer-
ence Diagnostic Center in Cairo in the
1990s [35]. At various time points, immune
responses against a panel of antigens were
determined in cohorts of humans living in
areas where they were regularly exposed to
infection and these results compared with
parasitological diagnosis. Cellular and hu-
moral immune responses were significantly
associated with either apparent resistance
or with apparent susceptibility to re-infec-
tion following chemotherapy. However,
onlya minorityoftheseresponsesproduced
consistent associations and the results were
seldom clear-cut. A similar investigation,
carried out in the Philippines [36], con-
firmedthe Egyptian findings, buta straight-
forward comparison was not possible
because some of the antigens tested were
different in the two studies. The discovery
of the surface-located tetraspanins Sm-
TSP-1 and TSP-2 as candidate vaccine
antigens resulted from a combination of
protective efficacy data obtained in the
S. mansoni murine challenge model with
their recognition by IgG1 and IgG3
antibodies from humans exposed but
resistant to schistosomiasis [37]. These
human studies are instructive for not only
identifying the few antigens directly and
exclusively associated with resistance, but
also for indicating which of these compo-
nents can be formulated with adjuvants to
generate protective responses in animal
models.
Concluding Remarks
Protection against schistosomiasis should
not only reduce infection and protect from
re-infection, but also accelerate immune
responses in infected humans directed
against granuloma-related pathology and/
or worm fecundity [22]. However, the
funding needed for a revised control
strategy will clearly not be forthcoming
without re-emphasizing the clinical dimen-
sion. Thus, rigorous re-calculation of the
true burden and societal impact of schisto-
somiasis, in the light of the new data on
mortality and morbidity (including ‘‘subtle
pathologies’’), is urgently needed [1,13,14].
There is no denying that schistosomiasis
vaccine development has followed a long
and tortuous road [22,24,38]. However,
the two vaccine candidates that have
progressed the furthest toward clinical
development—Sh28GST (at the Phase II
level) [26] and Sm14 (about to initiate
Phase I) [25]—demonstrate that this road
is negotiable.
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